Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
EXELALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, works toward building a potential second commercial franchise with zanzalintinib and moves its earlier
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
EXELALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises, on Wednesday, December 10, 2025, from 1:00 p.m. to 3:30 p.m. EST. During the event, featured speakers will review the progress of Exelixis’ R&D activities and outline the company’s strategy to advance future oncology franchises. These efforts underscore Exelixis’ continued focus on raising standards o
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
EXEL(NASDAQ:EXEL) LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or "the Company") (NASDAQ: EXEL) for violations of the securities laws. The...
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
EXEL(NASDAQ:EXEL) LOS ANGELES--(BUSINESS WIRE)---- $EXEL--EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
EXEL(NASDAQ:EXEL) ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company’s drug discovery, translational research, product development and medical affairs activities. "Dana has been an integral part of the Exelixis team for more than 25 years, with deep expertise that spans the drug discovery and development continuum. He's
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
EXELALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: 2025 Wells Fargo Healthcare Conference: Exelixis is scheduled to present at 12:45 p.m. ET / 9:45 a.m. PT on Wednesday, September 3 in Everett, MA. Citi’s 2025 Biopharma Back to School Conference: Exelixis is scheduled to present at 3:15 p.m. ET / 12:15 p.m. PT on Wednesday, September 3 in Boston. Morgan Sta
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
EXELNEW YORK, Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
EXELNEW YORK, Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation...
HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $47
EXELAnalyst Expectations For Exelixis's Future
EXELB of A Securities Maintains Neutral on Exelixis, Raises Price Target to $46
EXELExelixis To Present STELLAR-002 Trial Data At ASCO 2025 Showing Zanzalintinib Plus Nivolumab Achieved 63% Response Rate And 90% Disease Control In Untreated Advanced Clear Cell RCC, Alongside Additional Dose-Finding Results
EXELPrice Over Earnings Overview: Exelixis
EXELDemystifying Exelixis: Insights From 8 Analyst Reviews
EXELCitigroup Maintains Buy on Exelixis, Raises Price Target to $56
EXELExelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beat
EXELExelixis lifts 2025 revenue outlook after strong Q1 driven by Cabometyx sales surge and early traction in the neuroendocrine tumor market.
RBC Capital Reiterates Outperform on Exelixis, Maintains $40 Price Target
EXELExelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance
EXELExelixis beats Q1 estimates with strong Cabometyx sales, raises 2025 guidance, and begins Phase 1 trial of its novel NK cell engager, XB628.
Morgan Stanley Maintains Overweight on Exelixis, Raises Price Target to $47
EXELInvenra's Collaboration Partner Exelixis Initiates The Dose-Escalation Stage Of The First-In-Human Phase 1 Clinical Study Of XB628 In Participants With Recurrent Advanced Or Metastatic Solid Tumors
EXELExelixis Raises FY2025 Sales Guidance from $2.15B-$2.25B to $2.25B-$2.35B vs $2.25B Est
EXELExelixis Q1 Adj. EPS $0.62 Beats $0.36 Estimate, Sales $555.45M Beat $498.18M Estimate
EXELExploring Exelixis's Earnings Expectations
EXELIs the Market Bullish or Bearish on Exelixis?
EXELExpert Outlook: Exelixis Through The Eyes Of 19 Analysts
EXELJMP Securities Reiterates Market Outperform on Exelixis, Maintains $41 Price Target
EXELHC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $40 Price Target
EXELExelixis Announces U.S. FDA Approval Of CABOMETYX For Patients With Previously Treated Advanced Neuroendocrine Tumors
EXELExelixis To Present Preclinical Data For Four Pipeline Molecules At AACR Annual Meeting 2025
EXELWhat 25 Analyst Ratings Have To Say About Exelixis
EXELRBC Capital Maintains Outperform on Exelixis, Raises Price Target to $40
EXELPeering Into Exelixis's Recent Short Interest
EXELWells Fargo Downgrades Exelixis to Equal-Weight, Maintains Price Target to $36
EXELExelixis Board Authorizes Repurchase Of Up To An Additional $500M Of Common Stock Before December 31, 2025
EXELExelixis Reports Final 5-Year Follow-Up Results From CheckMate -9ER Trial Evaluating CABOMETYX In Combination With Opdivo In Patients With Advanced Kidney Cancer At ASCO GU 2025; Shows Survival Benefit Compared With Sunitinib; Long-Term Efficacy Seen Acro
EXELBarclays Maintains Equal-Weight on Exelixis, Raises Price Target to $29
EXELHC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $40 Price Target
EXELA Glimpse Into The Expert Outlook On Exelixis Through 21 Analysts
EXELCitigroup Maintains Buy on Exelixis, Raises Price Target to $45
EXELStephens & Co. Reiterates Equal-Weight on Exelixis, Maintains $29 Price Target
EXELStifel Maintains Hold on Exelixis, Raises Price Target to $36
EXELPiper Sandler Maintains Overweight on Exelixis, Raises Price Target to $38
EXEL15 Analysts Have This To Say About Exelixis
EXELTruist Securities Maintains Buy on Exelixis, Raises Price Target to $42
EXELJMP Securities Maintains Market Outperform on Exelixis, Raises Price Target to $41
EXELPiper Sandler Maintains Overweight on Exelixis, Raises Price Target to $37
EXELReported Earlier, Exelixis Reports $2.165B In Preliminary 2024 Revenue, Projects $2.15B-2.25B In 2025, And Highlights Pipeline Progress
EXELHC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $40
EXELThe FDA Has Notified Exelixis That The Supplemental New Drug Application For Cabometyx (Cabozantinib) For Previously Treated Advanced Pancreatic Neuroendocrine Tumors And Advanced Extra-pancreatic Patients Will No Longer Be The Subject Of Discussion At An
EXELBrookline Capital Initiates Coverage On Exelixis with Buy Rating
EXEL